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OBJECTIVES We sought to compare the neurohormonal responses and clinical effects of long-term,
high-dose versus low-dose enalapril in patients with chronic heart failure (CHF).
BACKGROUND Examination of neurohormonal and clinical responses in patients receiving different doses of
angiotensin-converting enzyme (ACE) inhibitors may provide insight into the potential for
additional suppression with angiotensin II (AT-II) or aldosterone antagonists.
METHODS Seventy-five patients with CHF were randomized to receive either high-dose (40 mg/day,
n  37) or low-dose (5 mg/day, n  38) enalapril over six months. The results from exercise
testing, echocardiography, tissue-specific ACE activity and monthly pre- and post-enalapril
neurohormonal levels were compared.
RESULTS Despite greater intra-group improvements in plasma renin activity and serum aldosterone
levels in the high-dose group, no statistically significant differences were observed between the
two groups in all variables, except for serum ACE activity at the end of study. Elevated serum
aldosterone and plasma AT-II levels were observed in 35% and 85% of patients, respectively,
at 34 weeks, an inter-group difference that was not statistically significant. A trend toward
higher levels of tissue-specific ACE activity in the high-dose group compared with the
low-dose group at the end of study was observed (p  0.054). A predefined composite end
point of clinical events had a trend toward better improvement in the high-dose group.
CONCLUSIONS This study could not demonstrate a difference between high- and low-dose enalapril in terms
of serum aldosterone and plasma AT-II suppression, despite a dose-dependent reduction in
serum ACE activity. Even at maximal doses of enalapril, elevated serum aldosterone and
plasma AT-II levels were frequently observed. (J Am Coll Cardiol 2002;39:70–8) © 2002
by the American College of Cardiology
Over the past decade, treatment with angiotensin-converting
enzyme (ACE) inhibitors has improved the prognosis of
patients with chronic heart failure (CHF). As the precise
mechanisms of angiotensin II (AT-II) and aldosterone gener-
ation in serum and tissue become increasingly understood, it is
apparent that ACE inhibitors may provide inadequate
long-term suppression of the renin-angiotensin-aldosterone
(RAA) system. This phenomenon, often known as “AT-II
reactivation” (1,2) or “aldosterone escape” (3,4), may con-
tribute to the persistently high morbidity and mortality rates
seen in patients with CHF, despite ACE inhibitor therapy.
See page 79
The dose-response characteristics of ACE inhibitors have
been explored as a potential factor in the development of
AT-II and aldosterone escape. Current strategies to coun-
teract this “escape” involve maximizing the ACE inhibitor
dose. However, two large-scale clinical trials have reported
inconclusive results on the potential benefits of high-dose
ACE inhibition as compared with lower doses (5,6). Mech-
anistically, few studies have carefully quantified the direct,
long-term impact of ACE inhibitor dosage on the degree of
neurohormonal suppression in advanced heart failure.
Therefore, we performed a prospective, randomized study
to describe the relationship between neurohormonal re-
sponses and the dose and timing of long-term enalapril
therapy in patients with CHF.
METHODS
Study subjects. Patients enrolled in this study had ad-
vanced heart failure of any etiology, with a clinical diagnosis
of New York Heart Association (NYHA) functional class
II–IV. Only those patients who had CHF (3 months
duration), with systolic dysfunction (left ventricular ejection
fraction 40%), already receiving treatment with digoxin
and diuretics were considered for the study. Subjects re-
cruited into the study were either not receiving ACE
inhibitors at the time of study entry or receiving ACE
inhibitors at very low doses (equivalent to enalapril 2.5
mg/day). Patients who would have required a reduction in
ACE inhibitor dose, those who had contraindications to
ACE inhibitors or who experienced a myocardial infarction
within the previous three months, were excluded.
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Study design. This was a prospective, single-center, ran-
domized, double-blind, parallel study comparing the neu-
rohormonal response and effects of high- and low-dose
enalapril regimens in 84 patients with advanced heart failure
(Fig. 1). After providing informed, written consent, all
patients had their history taken and underwent physical
examination, chest X-ray, electrocardiography, radionuclide
ventriculography and/or echocardiography, a chemistry
panel, a complete blood count and urinalysis for enrollment.
Patients enrolled in the study were started on or switched to
oral enalapril, 2.5 mg/day, and titrated to a steady dose of
2.5 mg twice daily for at least two weeks, in addition to
stable dosages of digoxin and diuretics. At the end of this
phase (defined as the “start” at week 4), repeated laboratory
studies and cardiopulmonary exercise testing were per-
formed and plasma neurohormone levels were obtained.
Patients were then randomized into two groups. For
patients randomized to high-dose enalapril, weekly dose
increments of 5 mg, 7 mg, 12.5 mg, 15 mg and 20 mg twice
daily of oral enalapril were given if there were no adverse
effects (e.g., hypotension, lightheadedness, dizziness) at
each increase in dose. For patients randomized to low-dose
enalapril, oral enalapril at 2.5 mg twice daily was continued
for six to eight weeks; the patients were subjected to a false
upward titration. During this phase, patients were clinically
evaluated weekly, with close monitoring of electrolytes and
kidney function, and repeated cardiopulmonary exercise
testing was performed and plasma neurohormone levels
obtained at the end of the upward titration (week 10).
Patients continued on their assigned enalapril doses for the
next six months. Their dosing schedules were converted
from twice daily to once daily. Throughout this phase,
patients were clinically evaluated weekly during the six-week
initial treatment phase, followed by a monthly clinical
evaluation, with close monitoring of electrolytes and kidney
function and measurement of serial plasma neurohormone
levels. At the end of the study (defined as the “end” at week
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
AT-II  angiotensin II
ARB  angiotensin II receptor blocker
CHF  chronic heart failure
NYHA  New York Heart Association
RAA  renin-angiotensin-aldosterone
Figure 1. Study protocol and withdrawal. Data are expressed as the number of patients withdrawn/discontinued from the trial. HD  high-dose; LD 
low-dose; qd  once daily; bid  twice daily; peak VO2  peak oxygen consumption.
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34), a complete physical examination, follow-up laboratory
tests, echocardiography and cardiopulmonary exercise test-
ing were performed and plasma neurohormone levels were
obtained.
Two-dimensional echocardiography was performed by an
experienced sonographer using a Hewlett-Packard ULS
machine (Hewlett-Packard Co., Medical Products Group,
Palo Alto, California), at 2.5 or 3.5 MHz, combining
imaging and Doppler transducer. Each patient was studied
in the left lateral decubitus position after 15 min of
recumbency. Cardiopulmonary exercise testing was per-
formed in the sitting position using an electrically braked
bicycle ergometer. The protocol started with a workload of
50 W and was increased in steps of 10 W; each step was
maintained for 1 min. Heart rate and blood pressure were
measured before and throughout the study, and standard
12-lead electrocardiograms were monitored continuously.
Plasma and serum neurohormone levels. Samples were
taken at baseline (week 10), as well as during monthly
follow-up visits at weeks 14, 18, 22, 26, 30 and 34 (Fig. 1).
All samples were taken from an 18-gauge angiocatheter in
an antecubital vein just before and 3 h after the morning
dose of enalapril. The patients were instructed to hold the
dose before the test and to rest in a supine position in a quiet
room for 30 min after venous cannulation and before blood
samples were taken. A total of 25 ml of blood was collected
in pyrogen-free, vacuum, blood-collection tubes (Becton
Dickinson, San Jose, California), with no additives (serum)
or with EDTA as an anticoagulant (plasma) or with
EDTA/glutathione plus a reducing agent (plasma). The
patients took their enalapril dose after completion of the
blood draw. The patients then returned in 3 h to repeat the
procedure.
All tubes were immediately immersed in melting ice and
centrifuged within 15 min before centrifugation at 1,000 g
and 4°C for 10 min. All samples were then stored at 80°C
in multiple aliquots until analysis. All samples were thawed
only once. Plasma renin activity was determined with an
immunoradiometric assay of the rate of angiotensin I
generation by plasma renin (Rianen Assay System angio-
tensin iodine-125 radioimmunoassay kit, NEA-104 or
NEA-105, DuPont, Boston, Massachusetts). Serum ACE
activity was determined by fluorometric measurement of the
rate of histidyl-leucine generation from a C-terminus cleav-
age of hippuryl-histidyl-leucine, a model substrate (modi-
fied from Cushman and Cheung [7]). Plasma AT-II levels
were measured by solid-phase extraction and subsequent
radioimmunoassay (AT-II iodine-125 radioimmunoassay
kit, American Laboratory Products Co., Windham, New
Hampshire). Serum aldosterone levels were determined by
solid-phase radioimmunoassay (Coat-A-Count aldosterone
kit, Diagnostic Products Corp., Los Angeles, California).
Plasma norepinephrine and epinephrine levels were deter-
mined by simultaneous radioenzyme assay of radioactive
O-methylated derivatives of norepinephrine and epineph-
rine (8). All normal values of neurohormonal levels were
reported from healthy subjects in a supine position for at
least 30 min.
Tissue ACE measurement. A subset of 17 patients (9 in
the high-dose group and 8 in the low-dose group) under-
went right ventricular endomyocardial biopsy where an
assay of tissue-specific ACE activity was performed at the
end of the study (week 34). Activity of ACE was deter-
mined in a grinded biopsy specimen, using the same
methods as described earlier for measuring plasma ACE
activity of tissue homogenates.
Statistical analysis. An intent-to-treat analysis of the two
groups of patients was performed after randomization.
Analysis of variance with repeated measures was used to
compare inter-treatment differences in the change from
baseline to the end of the study for the pre-dose, post-dose
and change measurements. Paired t tests were used to
compare these measurements within treatments. For the
composite end point, the Fisher exact test was used to
compare treatments. Differences in baseline characteristics
were evaluated by the chi-square test (categorical variables)
or the unpaired t test (continuous variables). A p value
0.05 was considered statistically significant.
RESULTS
Eighty-six patients were enrolled in the study, and 75
patients remained in the study after the open-label baseline
treatment phase at the time of randomization (Table 1).
Thirty-eight patients were randomized to the low-dose
group, and 37 patients were randomized to the high-dose
group. At the end of the study (week 34), 24 patients in the
low-dose group and 26 patients in the high-dose group
remained in the study for data analysis. As shown in Figure
1, there was no statistically significant difference in the rates
of drug discontinuation or adverse events between the two
groups.
Plasma/serum and tissue neurohormones. Pre-dose
(“trough” drug levels) and post-dose (“peak” drug levels)
responses of plasma and serum neurohormones after six
months of treatment with low-dose versus high-dose ena-
lapril are summarized in Table 2. Baseline (week 4) neuro-
hormonal levels were similar between the two groups before
and after oral administration of enalapril. After 34 weeks of
once-daily, oral enalapril therapy, only serum ACE activity
demonstrated statistically significant reductions (both pre-
and post-dose levels) between the low- and high-dose
groups (Fig. 2). Although there was adequate neurohor-
monal suppression after enalapril therapy (as indicated by a
large proportion of patients with serum ACE activity in the
normal control ranges), there was no statistically significant
difference in the level of post-dose plasma AT-II (Fig. 3) or
serum aldosterone (Fig. 4) levels between the two groups.
Similar findings were observed in the pre-dose analyses, as
well as in neurohormonal levels drawn at weeks 14, 18, 22,
26 and 30. In addition, a trend toward higher levels of
“tissue” ACE activity in the high-dose versus low-dose
72 Tang et al. JACC Vol. 39, No. 1, 2002
Neurohormones in High- and Low-Dose Enalapril January 2, 2002:70–8
group at the end of study was observed in a subgroup of 17
patients (0.498  0.27 vs. 0.330  0.1 nM/ml per m, p 
0.054).
Post-dose serum ACE activity levels were lower than
pre-dose levels in both groups. Only in the high-dose group
was there a significant fall in pre-dose serum ACE activity
at the end of the study. Similarly, a statistically significant
decrease in post-dose serum aldosterone levels (Fig. 4) and
increase in post-dose plasma renin levels (Fig. 5) were seen
only in the high-dose group between baseline and end of the
study. In both groups, at the end of the study, post-dose
serum aldosterone and AT-II levels were lower than the
pre-dose levels, whereas post-dose plasma renin activity was
higher than the pre-dose levels. There were no statistically
significant differences between plasma norepinephrine and
epinephrine levels in both the intra-group and inter-group
comparisons (Table 2). No correlation was observed be-
tween serum AT-II and aldosterone levels and serum
potassium levels throughout the study.
Clinical and functional outcomes. Overall, there was no
statistically significant difference between the two groups in
terms of changes in NYHA class and cardiopulmonary
exercise test results (Table 3). There were nearly twice the
number of predetermined patient events (e.g., emergency
room visits, hospital admissions, deaths, sustained increase
in diuretics dosage) in the low-dose group as compared with
the high-dose group, but this finding did not reach statis-
tical significance (p  0.061).
Echocardiographic data analysis. Over six months of
enalapril therapy, there was a trend toward a greater
reduction in left ventricular end-diastolic dimensions in the
high-dose group, but no significant changes were seen in the
low-dose group (p  0.08) (Table 4).
DISCUSSION
Neurohormonal modulation by high- versus low-dose
enalapril. The ability of ACE inhibitors to suppress neu-
rohormonal activation is considered to be the principal
mechanism of their therapeutic benefits in patients with
CHF. This is the first report of a rigorously performed,
serial, pre-dose and post-dose measurement study of plasma
neurohormones after long-term enalapril therapy in patients
with CHF. As shown in previous studies (9–11), a dose-
dependent relationship in the suppression of serum ACE
activity was observed. The lack of catecholamine suppres-
Table 1. Baseline Patient Characteristics at Randomization
(Week 4)
Low-Dose
Enalapril
(n  38)
High-Dose
Enalapril
(n  37)
Age (yrs) 51  12 52  11
Gender (male %) 87% 76%
Etiology
Idiopathic dilated 15 (40%) 22 (60%)
Ischemic cardiomyopathy 17 (45%) 9 (24%)*
Other 6 (15%) 6 (16%)
Symptoms
NYHA class II 1 (3%) 1 (3%)
NYHA class III 32 (84%) 36 (97%)
NYHA class IV 5 (13%) 0 (0%)
Duration (months) 41  54 34  42
Baseline medications
Diuretics 36 (95%) 34 (92%)
Digoxin 31 (82%) 30 (81%)
Beta-blockers 1 (3%) 2 (5%)
Amiodarone 9 (24%) 9 (24%)
Aspirin 9 (24%) 9 (24%)
Warfarin 23 (61%) 25 (68%)
Potassium supplement 30 (79%) 27 (73%)
Comorbid conditions
Diabetes mellitus 3 (8%) 3 (8%)
Hypercholesterolemia 16 (42%) 11 (30%)
Hypertension 15 (39%) 13 (35%)
Echocardiographic data
LVEF (%) 21  9 21  7
LVEDD (cm) 7.1  0.8 7.1  1.1
LVESD (cm) 6.1  0.9 6.2  1.3
Cardiopulmonary exercise
Duration (min) 8.9  2.9 9.3  2.8
Maximal HR (beats/min) 133  22 140  22
Peak V˙O2 (ml/kg per min) 15.7  4.9 17.0  5.4
*Statistically significant difference by the chi-square test. Data are presented as the
mean value  SD or number (%) of patients.
HR  heart rate; LVEDD  left ventricular end-diastolic diameter; LVEF  left
ventricular ejection fraction; LVESD  left ventricular end-systolic diameter;
NYHA  New York Heart Association; V˙O2  peak oxygen consumption.
Table 2. Changes in Plasma Catecholamine Levels and Serum Potassium and Creatinine Levels
After High-Dose Versus Low-Dose Enalapril Therapy
Baseline 34 Weeks
LDE HDE LDE HDE
Plasma epinephrine (pg/ml)
Pre-dose 43.8  34 36.8  35 47.4  38 38.6  33
Post-dose 51.5  42 46.0  40 45.5  38 40.2  29
Plasma norepinephrine (pg/ml)
Pre-dose 428.5  238 396.2  185 532.9  330 438.4  238
Post-dose 473.8  263 438.3  211 513.2  310 494.8  286
Potassium (mmol/l) 4.2  0.4 4.2  0.3 4.3  0.5 4.4  0.4
Creatinine (mg/dl) 1.2  0.3 1.1  0.2 1.2  0.5 1.2  0.3
*Intragroup statistical significance from pre-dose to post-dose: p  0.05. Data are expressed as the mean value  SD. Only
statistically significant results are reported from the comparisons: 1) between groups; 2) within a group, from pre-dose to
post-dose; and 3) within a group from baseline to 34 weeks.
HDE  high-dose enalapril; LDE  low-dose enalapril.
]* ]*
]*
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sion was also consistent with previous studies (9,12,13),
although a reduction in plasma norepinephrine levels had
previously been observed at high-dose ACE inhibition (14).
The finding of a lack of suppression in pre-dose serum ACE
activity emphasized two important aspects of measuring
plasma neurohormones in relation to drug therapy. First,
this shows the importance of meticulous control of the
timing of neurohormonal sampling in defining an accurate
observation; despite improvement seen in some post-dose
measurements, pre-dose measurements could be unaffected.
Second, the relatively small differences in pre-dose neuro-
hormone levels between the two groups and the inadequate
long-term suppression of aldosterone and AT-II, despite
high-dose enalapril therapy, may provide an explanation for
Figure 2. Serum angiotensin-converting enzyme (ACE) activity after high-dose versus low-dose enalapril therapy. Only statistically significant results are
reported from the comparisons: 1) between groups; 2) within a group (baseline to end of study); and 3) within a group (pre-dose to post-dose). In the first
two comparisons, the p value represents both pre- and post-dose results, unless otherwise stated. *p  0.05 pre-dose versus post-dose. Open bars  pre-dose
ACE activity; solid bars  post-dose ACE activity.
Figure 3. Plasma angiotensin II (AT-II) levels after high-dose versus low-dose enalapril therapy. Only statistically significant results are reported from the
comparisons: 1) between groups; 2) within a group (baseline to end of study); and 3) within a group (pre-dose to post-dose). *p  0.05 pre-dose versus
post-dose. Open bars  pre-dose AT-II level; solid bars  post-dose AT-II level.
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the relatively minor impact of enalapril dosing on clinical
variables observed in our study, as well as in other major
studies (5,6).
Like most previous neurohormonal studies (10 –
12,15,16), we found a wide variation of neurohormonal
levels both between different patients and between different
time intervals. It has been well known that collection times,
activity levels and presumably clinical stability have major
influences on subsequent neurohormonal levels. However,
even in stable patients with heart failure, Masson et al. (17)
observed coefficients of variations in neurohormone mea-
surements of up to 30%.
Previous clinical studies used a twice daily dosing of
enalapril (5,12,14,18). Once daily dosing of enalapril has
Figure 4. Serum aldosterone levels after high-dose versus low-dose enalapril therapy. Only statistically significant results are reported from the comparisons:
1) between groups; 2) within a group (baseline to end of study); and 3) within a group (pre-dose to post-dose). *p  0.05 pre-dose versus post-dose. Open
bars  pre-dose aldosterone level; solid bars  post-dose aldosterone level.
Figure 5. Plasma renin activity (PRA) after high-dose versus low-dose enalapril therapy. Only statistically significant results are reported from the
comparisons: 1) between groups; 2) within a group (baseline to end of study); and 3) within a group (pre-dose to post-dose). *p  0.05 pre-dose versus
post-dose. Open bars  pre-dose PRA level; solid bars  post-dose PRA level.
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been examined in small clinical studies and has been
suggested to be as effective as twice-daily dosing (19–21).
Mechanistic studies also showed that neurohormone levels
after once-daily enalapril dosing remain markedly sup-
pressed after 24 h (1,22), suggesting that once-daily dosing
has the potential to provide an effective 24-h impact on
neurohormone levels. Using a once-daily regimen, our study
demonstrated a statistically significant reduction in serum
ACE activity within the high-dose group after six months
of enalapril therapy, even at pre-dose (trough) levels. A 3-h
waiting interval was chosen for logistical reasons; however,
with the addition of the 30-min supine rest period before
the blood draw (total 3.5 h), this was close to the peak drug
effects seen 4 h after taking oral enalapril (23).
Suppression of tissue-specific ACE activity has been
suggested as a potential mechanism of reverse remodeling
by ACE inhibitors and has been observed in animal studies
(24). Surprisingly, a trend toward higher myocardial tissue-
specific ACE activity in the setting of lower serum ACE
activity was observed in the high-dose group as compared
with the low-dose group. Although these data were limited
by the small sample size, a discrepancy may exist between
ACE activity measured at the tissue level and that at the
serum level. The significance of this finding is unclear and
needs further validation. The inability to suppress tissue-
specific ACE activity by enalapril may provide an additional
mechanism to explain the persistently elevated serum aldo-
sterone and plasma AT-II levels, despite long-term enala-
pril therapy. The observed influence of ACE inhibitors
(especially peak effects at the high dose) on increasing
circulating plasma renin activity may also reduce the influ-
ence of ACE inhibitors on tissue components of the RAA
system. Further neurohormonal and clinical comparison
studies are needed to determine the significance of tissue-
specific ACE activity and to see whether tissue-specific
ACE inhibitors (such as ramipril and quinipril) would have
a larger impact on tissue-specific ACE suppression.
Aldosterone escape and AT-II reactivation. In both the
high- and low-dose groups, a significant degree of AT-II
reactivation and aldosterone escape was observed in the
pre-dose measurements at the end of the study. In an
open-label observation series of 81 patients, MacFadyen et
al. (25) found that post-dose AT-II reactivation occurred in
15% and failure of aldosterone suppression occurred in 38%
of patients with heart failure treated with ACE inhibitors
for no less than four months. Under similar circumstances,
we determined a similar rate of aldosterone escape (35%) in
our study group (39% in the low-dose group vs. 30% in the
high-dose group, p  NS by the chi-square test), whereas
significantly more patients (85%) demonstrated AT-II re-
activation (88% in the low-dose group vs. 81% in the
high-dose group, p  NS by the chi-square test) (Fig. 6).
The cut-off values of neurohormone levels were determined
from samples of normal control subjects and were similar to
those reported in previous studies (25). Our patient group
had a longer period of serum ACE inhibition (6 months)
and possibly more advanced disease, which may explain the
high percentage of AT-II reactivation and aldosterone
escape, even in the high-dose group. The relative lack of
plasma AT-II and the suppression of serum aldosterone in
both groups suggest that possible alternative pathways for
AT-II and aldosterone production have clinical relevance in
CHF. Our data provide a rationale for the results of the
Randomized ALdactone Evaluation Study (RALES) (26),
owing to the high proportion of patients who showed a
pre-dose elevation of serum aldosterone levels. These find-
ings also provide support for the theoretical role of combi-
nation therapy of ACE inhibitors with specific angiotensin
receptor blockers (ARBs), and this combination therapy was
recently supported by the clinical benefits seen in the
Valsartan in Heart Failure Trial (Val-HeFT) in patients
randomized to receive the addition of an ARB, although a
mortality benefit was not observed in the combined ACE
inhibitor/ARB group (27). The upcoming Valsartan in
Acute Myocardial Infarction Trial (VALIANT) should
Table 3. Clinical Outcomes After High-Dose Versus Low-Dose
Enalapril Therapy
LDE
(n  38)
HDE
(n  37)
p
ValueStart End Start End
Rest blood pressure (sitting)
Systolic (mm Hg) 111 109 112 115 NS
Diastolic (mm Hg) 70 68 71 70 NS
Rest heart rate (beats/min) 82.4 80.1 79.6 80.3 NS
NYHA functional class 3.1 2.9 3.0 2.8 NS
Cardiopulmonary exercise testing
Maximal heart rate (beats/min) 133 134 140 146 NS
Exercise duration (min) 8.9 9.3 9.3 9.9 NS
V˙O2 (ml/kg) 15.7 16.3 17.0 17.7 NS
Composite clinical end point 20 (53%) 11 (30%) 0.061
Death 3 (8%) 2 (5%)
Hospital admission 12 (32%) 9 (24%)
Emergency room visits 6 (16%) 1 (3%)
Sustained diuretic increase 8 (21%) 3 (8%)
Data are presented as the mean value or number (%) of patients.
Abbreviations as in Tables 1 and 2.
Table 4. Echocardiographic Responses After High-Dose Versus
Low-Dose Enalapril Therapy
LDE
(n  34)
HDE
(n  30)
p
ValueStart End Start End
LV dimensions
End-diastolic (cm) 7.1 7.3 7.1 6.9 0.08
End-systolic (cm) 6.1 6.1 6.2 5.9 NS
LV ejection fraction 24.4% 27.1% 21% 26.3% NS
RV dimensions
End-diastolic (cm) 2.27 2.26 2.38 2.01 NS
Posterior wall dimensions
End-diastolic (cm) 1.01 1.02 1.02 0.99 NS
End-systolic (cm) 1.25 1.41 1.28 1.44 NS
Mitral regurgitation grade (0–4) 1.31 1.41 1.59 1.36 NS
Data are presented as the mean value.
LV  left ventricular; RV  right ventricular; other abbreviations as in Table 2.
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provide further insights into the clinical impact of using
combinational neurohormonal suppression strategies (28).
Clinical effects of high- versus low-dose enalapril. Ena-
lapril was well tolerated, even at the 40-mg once-daily dose,
as compared with the 5-mg once-daily dose. In fact, there
were more reported adverse events and deaths (requiring
withdrawal from the trial) in the low-dose group than in the
high-dose group. As seen in previous studies, a large
proportion of patients with advanced CHF could receive up
to very high doses of enalapril without significantly more
adverse effects (29,30).
We did observe a trend toward improvement of ventric-
ular remodeling, although our study may have been under-
powered to detect a dose-dependent effect on ventricular
structural and functional changes after enalapril therapy.
The predefined composite clinical end point favored the
group randomized to the high dose and was very close to
statistical significance (p  0.06). In the light of the
conflicting results from previous ACE inhibitor dosing
studies (5,6,18), equivalence in some clinical variables be-
tween the high-dose and low-dose groups may not be too
surprising. However, as long-term follow-up of the Assess-
ment of Treatment with Lisinopril And Survival (ATLAS)
study has already indicated a statistically significant reduc-
tion in combined mortality and hospital admission rates,
when comparing high-dose with low-dose lisinopril (6), the
notion that high-dose ACE inhibition is superior to low-
dose therapy is likely to be valid, even though the degree of
benefit may be uncertain.
Study limitations. Our study was limited by a large with-
drawal rate within a six-month period, which may be
inevitable in patients with advanced heart failure, and may
be underpowered to detect statistically significant differ-
ences in neurohormone levels. Despite a total of 22 patients
who withdrew during the maintenance phase, randomiza-
tion to higher drug dosing of enalapril tended to be
associated with fewer withdrawals due to adverse events.
The wide variability in neurohormonal measurements may
have limited our abilities to detect other statistically signif-
icant differences within and between the two dosing groups.
Also once-daily dosing of enalapril may not provide ade-
quate neurohormonal suppression, as previously expected.
Patients in this study were not taking other neurohormonal
drugs, such as beta-blockers and spironolactone. Our results
might not be observed with different dosing regimens or
with other ACE inhibitor drugs with different pharmaco-
logic properties and different degrees of tissue affinity.
Nevertheless, our results confirmed the observation that in
this group of patients with advanced heart failure, high
concentrations of plasma AT-II and serum aldosterone
levels frequently exist, despite high-dose ACE inhibition.
Conclusions. This study could not demonstrate a differ-
ence between high-dose and low-dose enalapril in terms of
serum aldosterone and plasma AT-II suppression, despite a
Figure 6. Post-dose serum aldosterone escape and plasma AT-II reactivation after high-dose versus low-dose enalapril therapy at the end of the study (week 34).
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dose-dependent reduction in serum ACE activity. Trends
toward improved composite clinical end points and im-
proved cardiac structure and function were observed in the
high-dose group. Similar improvements in heart failure
symptoms, exercise capacity and adverse effects were seen in
both groups. Persistently elevated pre-dose serum ACE
activity and high degrees of aldosterone escape and AT-II
reactivation were observed in both groups, suggesting the
limitations of only once-daily enalapril therapy at com-
pletely suppressing these neurohormones, even at maximal
doses.
Reprint requests and correspondence: Dr. Michael B. Fowler,
Falk-CVRC 295, Stanford University Medical Center, Stanford,
California 94305. E-mail: mfowler@stanford.edu.
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